AstraZeneca, ai
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.
Monday, AstraZeneca Plc AZN released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...
James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the ...
AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback